Clavam 625mg (Co-Amoxiclav) Oxford — Amoxicillin-Clavulanate Infections | South East England UK 2026
PRODUCT NAME
Clavam 625mg Tablet (Co-Amoxiclav)
PRODUCT DETAILS
Clavam 625mg is a combination of amoxicillin 500mg + clavulanic acid 125mg, belonging to the penicillin class of antibiotics. Clavulanic acid helps protect amoxicillin from certain bacterial enzymes that can otherwise reduce its activity.
PRODUCT SPECIFICATION
- Generic Name: Co-Amoxiclav
- Active Ingredients: Amoxicillin 500mg + Clavulanic Acid 125mg
- Strength: 625mg total active ingredients
- Dosage Form: Film-coated tablet
- Drug Class: Penicillin / beta-lactam antibiotic
- Therapeutic Category: Antibacterial
- Route: Oral
- Prescription Status: Prescription medicine in the UK
KEY FEATURES
- Combines amoxicillin with clavulanic acid for broader activity against susceptible bacteria.
- Used for appropriately diagnosed bacterial infections, including certain sinus, respiratory, urinary, skin and soft-tissue, dental, and bone/joint infections.
- The 500mg/125mg formulation is an established UK co-amoxiclav tablet strength.
- Antibiotic selection should consider the suspected organism, infection site, severity and local antimicrobial-resistance guidance.
INDUSTRY UPDATE
Current UK medicines information continues to list co-amoxiclav 500mg/125mg tablets as an established formulation. UK guidance emphasizes appropriate antimicrobial use and consideration of bacterial susceptibility when selecting co-amoxiclav.
Patients with a history of serious allergy to penicillins or other beta-lactam antibiotics, or previous antibiotic-associated liver problems/jaundice, should discuss this with a doctor or pharmacist before treatment.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
FAQ 1: How does Oxford's university community — 25,000 undergraduates and 12,000 postgraduates — create specific Clavam 625mg infection demand?
The University of Oxford's student population — drawn from 150+ countries and concentrated in 39 colleges across Oxford's compact city centre — creates a densely connected community where bacterial infections spread efficiently. Oxford's residential college system: unlike campus universities, Oxford students live in small residential colleges (Balliol, Christ Church, Merton, Magdalen) where dining halls, libraries, and common rooms bring the same 200-400 students into repeated close contact — ideal for respiratory and GI pathogen transmission. The Oxford University Health Service (OUH primary care affiliate) — at 19 Beaumont Street — serves as the primary GP service for thousands of Oxford students; Clavam 625mg is prescribed here for dental abscess (prevalent in stressed finals-period students with poor dietary habits and dental neglect), complicated upper respiratory tract infections, skin infections, and bite wounds. Oxford's international student infection burden: Oxford's international students — 46% of graduate students are from outside the UK — bring travel-related infection history; international students returning from high-Beta-lactamase-prevalence countries (India, China, Brazil) may carry resistant organisms where Clavam 625mg's Beta-lactamase inhibition is specifically required. The Oxford college rowing culture: Oxford's Isis and Cherwell river rowing culture — with Torpids and Eights Week boat races on the Thames — creates skin infection and water-borne pathogen exposure; cuts from rowing accidents, Weil's disease (Leptospirosis from the Thames — Doxycycline, but sometimes Clavam for secondary bacterial infections), and cellulitis from prolonged water exposure all create antibiotic demand in Oxford's rowing community. Clavam 625mg from Unnati Pharmax at affordable cost serves Oxford's 2,000+ international graduate students outside full NHS GP registration during their first weeks in Oxford.
FAQ 2: How does Oxford's pharmaceutical and biomedical research heritage shape its approach to antibiotic prescribing?
Oxford has a unique place in antibiotic history — penicillin's clinical development happened at the Dunn School of Pathology on Oxford's South Parks Road in 1940-1941, where Howard Florey and Ernst Chain (who shared the Nobel Prize with Fleming) first demonstrated penicillin's clinical efficacy. AstraZeneca's global R&D headquarters (relocated from London to a new Cambridge campus but maintaining significant Oxford presence through the BioMedical Research Centre) and the Oxford Vaccine Group — which developed the Oxford-AstraZeneca COVID vaccine — give Oxford's research community an intimate relationship with pharmaceutical development. OUH's antimicrobial stewardship: Oxford University Hospitals' clinical pharmacology and microbiology departments have developed one of the UK's most sophisticated antimicrobial stewardship programmes — the OUH Antibiotic Handbook is a respected NHS resource used nationally. Clavam 625mg prescribing at OUH: OUH follows Oxfordshire Antimicrobial Guidelines (developed jointly by OUH and the Thames Valley Clinical Network) positioning Co-Amoxiclav as second-line or first-line where Beta-lactamase-producing organisms are the primary concern — consistent with national NICE guidance but incorporating Oxfordshire-specific resistance data. Oxford's clinical pharmacology culture: OUH's clinical pharmacologists have studied Co-Amoxiclav pharmacokinetics extensively — the Oxford PK/PD group has contributed to understanding of optimal Clavam dosing in renal impairment, a relevant consideration for Oxford's elderly Oxfordshire population accessing OUH from surrounding towns. Clavam 625mg from Unnati Pharmax at affordable cost serves Oxford patients who appreciate the scientific transparency of WHO-GMP generic equivalence — Oxford's research community is among the most capable of evaluating this evidence independently.
FAQ 3: How does Oxford's diverse global population — diplomatic families, NHS staff from 70+ countries — engage with Clavam 625mg?
Oxford's resident population is far more internationally diverse than its English-market-town character might suggest — OUH's NHS workforce includes doctors and nurses from India, the Philippines, Nigeria, Pakistan, and Egypt alongside Oxford's academic community of international researchers and the diplomatic families of personnel at the UK's Foreign Commonwealth & Development Office (FCDO) Hanslope Park facility (13km from Oxford). OUH's international workforce and Clavam: OUH employs hundreds of international medical graduates (IMGs) from South Asia and West Africa — these NHS workers are familiar with Co-Amoxiclav formulations from their countries of origin (widely prescribed as generic Co-Amoxiclav in India, Nigeria, and Pakistan) and are among Oxford's most informed Clavam users. The Clarendon Fund and Rhodes Scholars: Oxford's Clarendon Scholarship (one of Oxford's largest graduate scholarship programmes) and the Rhodes Scholarship (100 international scholars annually) bring elite students from Africa, Asia, and the Americas whose bacterial infection treatment during their Oxford studies requires NHS GP registration — a process that takes 2-4 weeks from arrival; Clavam 625mg from Unnati Pharmax at dramatically reduced cost bridges this registration gap for Clarendon and Rhodes Scholars who develop dental or respiratory infections during their first weeks. Oxford's South Asian community in Cowley: Oxford's East Oxford neighbourhood of Cowley has a significant South Asian community — Pakistani and Bangladeshi families who provide Oxford's restaurant, retail, and logistics workforce; Clavam 625mg serves this community through OUH's John Radcliffe Hospital outpatient clinics and Oxford's numerous GP practices, with affordable private supply from Unnati Pharmax for those in NHS registration transitions.
FAQ 4: What are Clavam 625mg's key pharmacological advantages over plain Amoxicillin — as understood by Oxford's scientifically literate patient population?
Oxford's research-literate patient population — including medical students, clinical pharmacologists, and pharmaceutical company scientists — engages with antibiotic prescribing rationale at a level of scientific depth unique among UK cities. Clavulanic Acid's mechanism: Clavulanic Acid is a beta-lactam compound (sharing the core ring structure with penicillins) that acts as a suicide inhibitor of bacterial beta-lactamase enzymes — it binds irreversibly to the active site of beta-lactamase, permanently inactivating the enzyme; the Amoxicillin component can then reach its target (penicillin-binding proteins, PBPs) and inhibit bacterial cell wall synthesis without being destroyed. The clinical benefit: the addition of Clavulanic Acid extends Amoxicillin's spectrum to include: Haemophilus influenzae (prevalent cause of sinusitis and LRTI in Oxfordshire's population — approximately 25-35% of H. influenzae isolates are beta-lactamase-producing in Oxfordshire); Moraxella catarrhalis (virtually all strains are beta-lactamase-producing); Staphylococcus aureus (MSSA — 90%+ of community S. aureus are beta-lactamase-producing, making plain Amoxicillin ineffective); and certain Klebsiella and E. coli strains in urinary and wound infections. When Oxford patients ask whether Clavam 625mg is "stronger" than Amoxicillin: OUH's clinical pharmacologists clarify that "broader-spectrum" is more accurate — the Clavulanic Acid inhibitor adds coverage against beta-lactamase-producing organisms rather than increasing the potency against organisms already sensitive to Amoxicillin. Clavam 625mg from Unnati Pharmax at affordable cost enables Oxford's research-community patients to access the WHO-GMP certified generic whose pharmacological profile they understand at a mechanistic level — a particularly appropriate match for Oxford's scientifically engaged patient base.
FAQ 5: How does OUH Oxford's NHS antimicrobial stewardship programme guide Clavam 625mg appropriate use?
OUH's Antimicrobial Stewardship Programme — awarded ESCMID's European Antibiotic Awareness Day commendation in 2024 — applies both national PHE/UKHSA guidance and Oxfordshire-specific resistance surveillance data to Clavam 625mg prescribing. OUH's Clavam 625mg appropriate use criteria: dental abscess with spreading infection — first-line at OUH dental emergency service; dog and cat bite wound infections — first-line (Pasteurella multocida coverage); diabetic foot mild-moderate infections — first-line; complicated community URTI where H. influenzae Beta-lactamase prevalence makes plain Amoxicillin insufficient; and sinusitis requiring antibiotics (second-line after Amoxicillin failure, or first-line in high-risk patients). OUH's electronic prescribing stewardship alert: OUH's Epic electronic prescribing system generates alerts for Clavam 625mg orders that don't match approved indications — specifically flagging Clavam prescribed for viral URTI presentations where antibiotics are not indicated; this reduces inappropriate Clavam use across OUH. Duration guidance: OUH limits Clavam 625mg to 5-7 days for URTI and skin infections, 5 days for dental infections, and 10-14 days only for complicated diabetic infections — minimising total antibiotic exposure while achieving clinical cure. Clavam 625mg from Unnati Pharmax at dramatically reduced cost serves Oxford patients who receive appropriate Clavam prescriptions from OUH or Oxford GP practices and need affordable access during prescription processing — ensuring that appropriate antibiotic courses are completed without cost-related early termination that could compromise infection clearance
Website
Email Id
Contact Number
+91-8265041513
Clavam-625-mg-Co-Amoxiclav-Oxford
